Efgartigimod for first-time optic neuritis
Treatments studied
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This trial tests a drug called efgartigimod for people having their first episode of optic neuritis (inflammation of the optic nerve). The goal is to see if it can help protect your vision better than standard treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are having your first-ever episode of optic neuritis (inflammation of the optic nerve)
- Your vision changes started within the last 10 days
- You have not received more than 3 days of high-dose steroids for this episode
- You do not have a prior diagnosis of MS, NMOSD, or MOGAD
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new medication called privosegtor can help restore vision in people who recently experienced sudden vision loss in one eye due to optic nerve inflammation. You would receive the study drug early after your symptoms start, when treatment may be most effective.
This Phase 2 trial tests whether clemastine can help regrow the protective covering around the optic nerve after acute optic neuritis (an inflammation-related vision problem). It may help improve vision recovery and signal how well “remyelination” happens.
This study evaluates new guidelines for diagnosing optic neuritis, a condition where the nerve that carries vision becomes inflamed. If you have sudden vision loss in one or both eyes and your doctor thinks optic neuritis might be the cause, this trial will help confirm the diagnosis using updated diagnostic criteria.
This trial tests a drug called efgartigimod for people having a sudden worsening of NMOSD symptoms. It targets a protein to reduce attack severity and is given alongside standard care.
This trial tests a medicine called efgartigimod to treat autoimmune encephalitis (AIE)—a rare condition where the immune system attacks the brain. The study enrolls children 12+ and adults to see if this drug can reduce symptoms and help recovery.
This study tests a new treatment called efgartigimod for people who have been recently diagnosed with generalized myasthenia gravis (gMG). It aims to see if this medicine can help manage symptoms like muscle weakness.
Hear when a new Optic Neuritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.